Merck Strengthens its Presence in China with New Pharmaceutical Manufacturing Facility

19-Nov-2013 - China

Merck announced a € 80 million investment in a new pharmaceutical manufacturing facility, to be located in the Nantong Economical Technological Development Area (NETDA), in the Greater Shanghai region (Yangtze River Delta area).

“This further investment in China reflects Merck’s long-term commitment to the country where our group has been present for 80 years,” said Belén Garijo, President and Chief Executive Officer of Merck Serono, the biopharmaceutical division of Merck. “We are proud to be one of the first multinational companies investing in a local site focused on the manufacturing of medicines referenced in China’s essential drug list, and serve the country’s expanding healthcare needs in the areas of diabetes, cardiovascular diseases and thyroid disorders, by bringing high-quality medicines made in China to a broader population, in full alignment with the Chinese government’s goal to increase access to quality products.”

The new facility will focus on the bulk production and packaging of Glucophage®, Concor® and Euthyrox®, Merck’s leading brands for the treatment of diabetes, cardiovascular diseases and thyroid disorders respectively. Located in NETDA’s BioSpark, a high-tech industrial park designed to accommodate all aspects of the life science industry, the new facility will cover an area of 40,000 square meters, with a possible 20,000 square meters extension. The construction of the site is scheduled to start in 2014 and to be completed in 2016, and start commercial production in 2017.

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances